Slides
Page 1
A global industrial leader in attractive specialty chemicals niches and in pharmaceutical packaging Full Year 2025 results Media and Investors' Conference February 18, 2026
Page 2
Disclaimer CPH Group Media and Investors' Conference of 18 February 2026 2 Investing in the shares of CPH Group AG involves risks. Prospective investors are urged to consult their investment advisors and tax advisors prior to investing in CPH Group AG shares. This document contains forward-looking statements which involve risks and uncertainties. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumedto update any forward-looking statements. Potential risks and uncertainties include such factors as general economic conditions, foreign exchange fluctuations, competitive product and pricing pressures and regulatory developments. The information contained in this document has not been independently verified and no representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information in this presentation is subject to change without notice, it may be incomplete or condensed, and it may not contain all material information concerning the CPH Group. Neither CPH Group AG nor its affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchaseany shares, and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This information does not constitute either an offer to buy shares of CPH Group AG or a prospectus within the meaning of the applicable Swiss law.
Page 3
Agenda CPH Group Media and Investors' Conference of 18 February 2026 3 Highlights 2025 Peter Schaub Business development Alois Waldburg-Zeil Financial results Gerold Brütsch Strategy and Outlook Alois Waldburg-Zeil
Page 4
2025 in brief First full financial year of CPH Group without the spun-off paper division Strategic acquisitions at Zeochem (high-value chromatography gels) and Perlen Packaging (vials and containers) strengthen product portfolios and market positions Strong profitable growth of chromatography gels and deuterated products segments Overall headwind through tariffs, forex and geopolitical tensions Profitability of Blister Packaging temporarily impacted by product mix and new capacities in the market (pricing/volumes) Unchanged dividend of CHF 2.00 reflecting the company’s overall confidence (proposal to AGM) CPH Group Media and Investors' Conference of 18 February 2026 4
Page 5
Agenda Highlights 2025 Peter Schaub Business development Alois Waldburg-Zeil Financial results Gerold Brütsch Strategy and Outlook Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 5
Page 6
Key figures 2025 at a glance Sales in CHF million 334 (2024: 323) EBITDA in CHF million 50 (2024: 54) Net result in CHF million 23 (2024: 34) Free cash flow in CHF million 16 (2024: 35) Equity ratio in % 55 (2024: 63) EBITDA margin in % 15 (2024: 17) CPH Group Media and Investors' Conference of 18 February 2026 6
Page 7
CPH is a global industrial leader in attractive specialty chemicals niches and in pharmaceutical packaging Differentiation through high customer benefit Worldwide amongst Top 3 in molecular sieves for healthcare and industrial applications and deuterated products Zeochem 115 Sales 24 EBITDA Differentiation through high customer benefit Worldwide amongst Top 3 for coated barrier films for pharmaceutical applications and complementary primary medicinal packaging Perlen Packaging 219 Sales 26 EBITDA Key figures for 2025 in CHF million Leading market positions Strong brands Focused growth strategy Global footprint CPH Group Media and Investors' Conference of 18 February 2026 7
Page 8
Strong global megatrends and focused strategies drive growth Division Sales share 76% Megatrends Markets Applications Products Pharmaceutical packaging Molecular sieves Chromatography gels Deuterated products PharmaceuticalsHealth & Demography Medicines Respirators Medical oxygen API Molecular sievesIndustryEnergy Natural gas/LNG Ethanol Hydrogen 11% CPH Group Media and Investors' Conference of 18 February 2026 8 Zeochem Perlen Packaging
Page 9
Zeochem CPH Group Media and Investors' Conference of 18 February 2026 9
Page 10
Zeochem – strategic highlights 2025 Focus on high-value specialties in global niche markets Vadodara 2024 Louisville 1979 Donghai 2016 Zvornik 2018 Rüti* 2018 Québec 2025 Paris 2025 Shanghai 2015 Singapore 2009 o Highly valuable acquisition of SiliCycle, a global leader in pharma-grade chromatography gels based in Canada o Integration of SiliCycle enables building a global chromatography gels platform across Europe, Asia and North America o Successful integration of Sorbchem (acquired 2024) strengthened market position in India o Capacity expansion for deuterated compounds in Rüti/CH o Focus on advancing Zeochem’s strategy in high-value specialized applications in global niche markets CPH Group Media and Investors' Conference of 18 February 2026 10
Page 11
0 20 40 60 80 100 120 140 2021 2022 2023 2024 2025 0% 5% 10% 15% 20% 25% 0 5 10 15 20 25 2021 2022 2023 2024 2025 SALES EBITDA CAGR 4.8% Zeochem New record EBITDA and improved EBITDA margin o Growth in high-quality molecular sieves for natural gas purification and in deuterated solvents o Chromatography gels recorded significant growth thanks to the acquisitions of Sorbchem India in 2024 and SiliCycle in 2025 o Sales down for lithium-based products following slight declines in lithium costs and passing on the resulting savings to customers o New record EBITDA (CHF 24 million) and higher EBITDA margin (21%) o Stable market for applications of deuterated compounds and chromatography gels; deuterated compounds with profitable annual sales growth averaging 21% over the last five years o Economic uncertainties dampen demand for molecular sieves; overcapacity among competitors put pressure on molecular sieve prices o Strong momentum in Asia, subdued development in Europe and the US Market environment Business development % of sales (EBITDA margin) in CHF million in CHF million CPH Group Media and Investors' Conference of 18 February 2026 11
Page 12
Perlen Packaging CPH Group Media and Investors' Conference of 18 February 2026 12
Page 13
Perlen Packaging – strategic highlights 2025 Specialist for pharmaceutical packaging o Strategic portfolio expansion into complementary primary pharmaceutical packaging o LOG Pharma is an established pharma and medical packaging manufacturer with sites in Israel and Hungary o Sales synergies in a growing oral drug packaging market o LOG portfolio crucial for expansion into US market o Enhanced access to Eastern European markets via Hungary o Further strengthening the targeted growth strategy Whippany 2006 Müllheim 2007 Anápolis 2018 Perlen 1954 Suzhou 2016 Tököl 2025 Ashdot Ya’akov Ihud 2025 CPH Group Media and Investors' Conference of 18 February 2026 13
Page 14
SALES EBITDA CAGR 6.5% Perlen Packaging Acquisition-driven growth – but a temporary decline in profitability o Sales +6.5% due to LOG Pharma acquisition o Lower EBITDA due to overcapacity, tariffs, exchange rate effects, product mix and a slightly higher cost base in CH o Cost reduction program and further optimizations initiated o Integration of LOG Pharma progressing, sales do not yet meet expectations due to customer-related order adjustments o New cutting and packaging lines operational in Switzerland, Brazil and the US o New capacities in Europe and sluggish economic environment put pressure on volumes and prices o Raw material prices declined slightly o Higher energy and transportation costs Market environment Business development 0 50 100 150 200 250 2021 2022 2023 2024 2025 0% 5% 10% 15% 20% 25% 0 10 20 30 40 50 2021 2022 2023 2024 2025 % of sales (EBITDA margin) in CHF million in CHF million CPH Group Media and Investors' Conference of 18 February 2026 14
Page 15
Agenda Highlights 2025 Peter Schaub Business development Alois Waldburg-Zeil Financial results Gerold Brütsch Strategy and Outlook Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 15
Page 16
ROCE in % Free cash flow in CHF million Sales in CHF million Sales by application in CHF million Sales by region in CHF million Key figures CPH Group 1 76% of sales from health market 0 5 10 15 20 25 2021 2022 2023 2024 2025 0 100 200 300 400 2021 2022 2023 2024 2025 CAGR 5.9% 1 continued divisions CPH Group Media and Investors' Conference of 18 February 2026 16 0 100 200 300 400 2021 2022 2023 2024 2025 Europe The Americas Asia Rest of World 0 100 200 300 400 2021 2022 2023 2024 2025 Health & Demography Energy Other EBITDA and EBITDA margin in CHF million / in % 0% 5% 10% 15% 20% 0 20 40 60 80 2021 2022 2023 2024 2025 0 20 40 60 2021 2022 2023 2024 2025
Page 17
2025 Financial Year Consolidated Income Statement I in CHF millions 2025 % 2024 1 % ± ±% Net sales 334.1 100.0 323.3 100.0 +10.8 +3.3% Other operating income 3.2 1.0 3.8 1.2 Change in inventories - - 0.5 0.2 Cost of materials -161.2 -48.3 -166.9 -51.7 Cost of energy -13.3 -4.0 -11.3 -3.5 Gross profit 162.8 48.7 149.4 46.2 +13.4 +9.0% Personnel expense -79.5 -23.8 -67.3 -20.8 Other operating expense -33.0 -9.9 -28.3 -8.8 EBITDA 50.3 15.0 53.8 16.6 -3.5 -6.5% 1 continued divisions Net sales 3.3% above prior-year, thereof +8.1% from acquisitions and -3.8% due to FX. Organic decline in particular due to geopolitical uncertainties and lower raw material prices, which had been passed on to the customers. Gross profit increased by 9.0% or CHF 13.4 million mainly due to acquisitions. Gross profit margin of 48.7% clearly above prior year (46.2%). Personnel and other operating expenses above prior year mainly due to acquisitions. EBITDA of CHF 50.3 million and EBITDA margin of 15.0% slightly below prior year. CPH Group Media and Investors' Conference of 18 February 2026 17 1 2 3 4 3 1 2 4 3
Page 18
in CHF millions 2025 % 2024 1 % ± ±% EBITDA 50.3 15.0 53.8 16.6 -3.5 -6.5% Depreciation expense -17.5 -5.2 -14.6 -4.5 Operating result EBIT 32.8 9.8 39.2 12.1 -6.4 -16.3% Financial result -2.8 -0.8 0.3 0.1 Non-operating result -0.1 -0.1 2.1 0.7 Result before income taxes 29.9 8.9 41.6 12.9 -11.7 -28.2% Income taxes -6.5 -1.9 -7.2 -2.2 Net result 23.4 7.0 34.4 10.7 -11.0 -32.0% Earnings per share (in CHF) 3.90 5.74 -1.84 1 continued divisions 2025 Financial Year Consolidated Income Statement II Depreciation and amortization above prior year as a consequence of the Sorbchem, LOG Pharma and SiliCycle acquisitions. EBIT margin further down than EBITDA margin due to acquisition-related higher depreciation and amortization. Positive one-time impacts in financial and non- operating result in the prior year. Acquisition-related higher interest expenses. Income tax expense at 21.6% (prior-year 17.2%) slightly above the expected mid-term range of 18-20%. Net result and earnings per share down by 32.0% due to lower EBIT combined with one-time impacts in the prior year and higher interest expenses. CPH Group Media and Investors' Conference of 18 February 2026 18 1 2 3 4 5 5 3 1 2 3 4 5
Page 19
in CHF millions 31.12.2025 % 31.12.2024 % ± ±% Cash and cash equivalents 27.0 7.3 31.6 9.5 Trade receivables 56.5 15.3 48.3 14.5 Inventories 80.1 21.7 74.8 22.5 Other current assets 13.8 3.8 14.9 4.5 Fixed assets 191.5 51.9 163.0 49.0 Total assets 368.9 100.0 332.6 100.0 +36.3 +10.9% Financial liabilities 53.2 14.4 18.9 5.7 +34.3 +181% Trade payables 33.7 9.1 34.1 10.3 Other liabilities 37.2 10.1 33.8 10.1 Provisions 40.9 11.1 36.4 10.9 Shareholders' equity 203.9 55.3 209.4 63.0 -5.5 -2.7% Total liabilities and equity 368.9 100.0 332.6 100.0 +36.3 +10.9% Operating net working capital 78.3 21.2 67.6 20.3 +10.7 +15.9% Capital employed 244.1 66.2 208.3 62.6 +35.8 +17.2% Net debt 26.2 7.1 -12.7 -3.8 +38.9 n.a. 2025 Financial Year Consolidated Balance Sheet Increase in total assets by CHF 36.3 million, CHF 48.7 million from acquisitions. Financial liabilities increased by CHF 34.3 million to finance the LOG Pharma and SiliCycle acquisitions. Solidly financed with an equity ratio of 55.3%. Increase in operating net working capital by CHF 10.7 million (CHF 9.2 million from acquisitions). Increase in capital employed by CHF 35.8 million, CHF 38.3 million from acquisitions. Net debt of CHF 26.2 million, prior year net cash of CHF 12.7 million. Low leverage ratio of 0.5x (Net debt / EBITDA). CPH Group Media and Investors' Conference of 18 February 2026 19 1 2 3 4 5 6 1 2 3 4 5 6
Page 20
in CHF millions 2025 % 2024 1 % ± ±% Net result 23.4 7.0 34.4 10.7 -11.0 -32.0% Non-cash items 19.1 5.7 8.5 2.6 Cash flow 42.5 12.7 42.9 13.3 -0.4 -0.9% Change in net working capital -8.4 -2.5 10.4 3.2 Cash flow from operating activities 34.1 10.2 53.3 16.5 -19.2 -36.1% Purchase of subsidiaries -33.2 -9.9 -32.8 -10.1 Capital expenditures -21.2 -6.4 -20.4 -6.3 Disposal of fixed assets 3.5 1.1 1.9 0.5 Cash flow from investing activities -50.9 -15.2 -51.3 -15.9 +0.4 -0.7% Increase/Repayment of financial liabilities 25.8 7.7 18.1 5.6 Purchase/sale of own shares -0.3 -0.1 -0.5 -0.2 Distribution to shareholders -12.0 -3.6 -24.0 -7.4 Cash flow from financing activities 13.5 4.0 -6.4 -2.0 +19.9 n.a. Currency translation -1.3 -0.4 0.6 0.2 Change in cash and cash equivalents -4.6 -1.4 -3.8 -1.2 -0.8 +20.7% Free cash flow 2 16.4 4.9 34.9 10.5 -18.5 -53.1% 1 continued divisions 2 before acquisition of subsidiaries 2025 Financial Year Consolidated Cash Flow Statement Non-cash items include depreciation and amortization and change in provisions. Cash flow before change in net working capital at prior year level. Change in net working capital due to timing effects. Acquisitions of LOG Pharma and SiliCycle in 2025 as well as Sorbchem in 2024. Capital expenditure include capacity (42%), efficiency (33%), replacement (15%) and other (10%). Free cash flow of 4.9% below target range of 8-10% due to lower EBITDA and temporary seasonal increase in net working capital. 1 CPH Group Media and Investors' Conference of 18 February 2026 20 2 3 4 5 6 1 2 3 4 5 6
Page 21
2025 Financial Year Segment Results in CHF millions 2025 2024 ± % 2025 2024 ± % 2025 2024 1 ± % Net sales 114.7 117.3 -2.2% 219.4 206.0 +6.5% 334.1 323.3 +3.3% EBITDA 23.9 22.8 +4.5% 25.9 33.3 -22.2% 50.3 53.8 -6.5% EBITDA margin 20.8% 19.5% 11.8% 16.1% 15.0% 16.6% EBIT 15.1 14.9 +1.6% 17.1 26.6 -35.7% 32.8 39.2 -16.3% EBIT margin 13.2% 12.7% 7.8% 12.9% 9.8% 12.1% Headcount (FTE) 452 406 +11.3% 784 546 +43.6% 1'244 959 +29.7% 1 continued divisions CPH GroupZeochem Perlen Packaging Net sales 2.2% below prior-year, currency and acquisition adjusted unchanged (+/- 0.0%), volume growth compensated by lower raw material prices, which had been passed on to the customers. Increase in EBITDA margin to 20.8% and highest ever EBITDA due to growth in high-value products. EBIT affected by acquisition-related higher depreciation and amortization. Net sales 6.5% above prior-year, currency and acquisition adjusted -1.5%, organic volume growth with shift towards monoblister and lower raw material prices. Decrease in EBITDA margin to unsatisfactory 11.8%, cost reductions and optimizations initiated. EBIT affected by acquisition-related higher depreciation and amortization. CPH Group Media and Investors' Conference of 18 February 2026 21 1 2 3 4 5 6 1 2 3 4 5 6
Page 22
Sustainable corporate management Progress in implementing sustainability strategy Sustainable value creation o Long-term corporate purpose embedded o Assessment of ESG-driven market opportunities Net-zero strategy o Striving for net zero o Preparing an appropriate stage plan, while maintaining competitiveness o 92% of emissions from upstream and downstream value chain Responsible employer o Remain an attractive and careful employer o Ensuring equal rights o High engagement index of 80% Transparency & governance o ESRS-oriented ESG reporting o SBTi commitment by Perlen Packaging o Ethical supply chain o Board committee for sustainability implemented Circular economy & innovation o Expanding circular portfolio o 83% of waste recovered Short- and mid-term priorities o CO2 transparency and reduction path o Implementing ESG strategy plan o Considering ESG aspects in every business decision CPH Group Media and Investors' Conference of 18 February 2026 22
Page 23
Agenda Highlights 2025 Peter Schaub Business development Alois Waldburg-Zeil Financial results Gerold Brütsch Strategy and Outlook Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 18 February 2026 23
Page 24
Strategy and Outlook A solid basis for an attractive investment case Among the top 3 in attractive niche markets with above average growth potential Taking profit of the global megatrends health & demography and energy Continuous expansion of market position with a focus on growth regions and emerging markets Proven M&A and integration skills to widening offering and global footprint Strong balance sheet and highly engaged employees CPH Group Media and Investors' Conference of 18 February 2026 24
Page 25
Strategy and Outlook Main growth initiatives to exploit sales and margin potential Sales push Innovation Capacity utilization India Bottle packaging and Eastern Europe entry High-value chromatography gels Brazil Strengthening of sales organizations in attractive niche markets Widening of product portfolio to meet customer needs and create value Increasing capacity utilization worldwide The strategic acquisition of Sorbchem in 2024 created the hub for the expansion of the business in fast growing India Complementing pharmaceutical packaging offering and access to new markets through LOG Pharma Complementing offering with derivatized chromatography gels from SiliCycle Ramp-up Brazilian operation established in 2023 to full capacity (greenfield pharmaceutical packaging coating facility) CPH Group Media and Investors' Conference of 18 February 2026 25
Page 26
Outlook 2026 Back to profitable growth in both divisions o Sales and EBITDA above previous year o Complete integration of LOG Pharma o Sales and EBITDA above previous year o Complete integration of SiliCycle Perlen PackagingZeochem CPH Group o Market conditions volatile and challenging o Long-term megatrends of health & demography and energy intact o Stronger portfolio and footprint in high-value specialties in global niche markets and exploiting synergies in packaging offer substantial growth potential and attractive margins o Sales, EBITDA, EBIT and net income are all expected to exceed 2025 figures CPH Group Media and Investors' Conference of 18 February 2026 26
Page 27
Strategy and Outlook Mid-term financial targets unchanged Growth Sales increase 5-8% p.a. Profitability EBITDA margins 16-18% Cash flow Free cash flow margins 8-10% Financing Equity ratio >50% Dividend Payout ratio 25-50% CPH Group Media and Investors' Conference of 18 February 2026 27
Page 28
Q&A CPH Group Media and Investors' Conference of 18 February 2026 28
Page 29
Share price development in CHF Information for shareholders Market capitalisation as of 31.12.2025 in CHF million 415 6 million registered shares of CHF 0.15 nominal value 0 20 40 60 80 100 2021 2022 2023 2024 2025 SPIX_adjusted CPHN_rebased Dividend policy o Payout ratio of 25% to 50% of net income o Taking into account liquidity, free cash flow, and the relevant forecasts Shareholder structure 2025 2024 2023 2022 2021 Distribution per share (in CHF) 2.00 2.00 2.281 1.151 1.301 Dividend yield (as of 31.12.) 2.9% 2.7% 3.7%2 2.1%2 3.0%2 33.6% 6.0% 3.2%57.2% Shareholder group Elly Schnorf-Schmid Stiftung and Swiss Industrial Finance AG (represented by Peter Schaub) J. Safra Sarasin Investmentfonds AG UBS Fund Management (Switzerland) AG Free float 1 adjusted for the indicative share of around 28% of spun-off Perlen Industrieholding AG CPH Group Media and Investors' Conference of 18 February 2026 29 SPIX adjusted CPHN1 1 share from continued divisions based on share of earnings per share 2 continued divisions, adjusted for the indicative share of around 28% of spun-off Perlen Industrieholding AG
Page 30
Calendar and contacts Calendar 17.03.2026 Annual General Meeting, Lucerne 21.07.2026 Publication of 2026 Half-Year Report 10.09.2026 CPH Group Investors‘ Day in Zurich 18.02.2027 Media and Investors' conference Publication of 2026 annual report 16.03.2027 Annual General Meeting, Lucerne CPH Group Media and Investors' Conference of 18 February 2026 30 Contacts Gerold Brütsch CFO +41 41 455 87 67 investor.relations@cph.group Oliver Seifried Head of Corporate Communications +41 41 455 87 51 medien@cph.group Alois Waldburg-Zeil CEO +41 41 455 87 67 Analysts Baader Helvea Volker Bosse Research Dynamics Alexandre Müller Research Partners Eugen Perger Zürcher Kantonalbank Tobias Klöpper
Page 31
CPH Group Media and Investors' Conference of 18 February 2026 31 20102025 Business locations worldwide Consistent and ongoing internationalization over the last 15 years Whippany 2006 Müllheim 2007 Anápolis 2018 Tököl 2025 Ashdot Ya’akov Ihud 2025 Louisville 1979 Zvornik 2018 Rüti* 2018 Québec 2025 Whippany 2006 Müllheim 2007 Perlen 1954 Louisville 1979 Perlen 1954 Suzhou 2016 Donghai 2016 Zeochem Perlen Packaging Uetikon 1818 Vadodara 2025
Page 32
Zeochem – top global niche player in specialty chemicals Leading market position backed by global megatrends Vadodara 2024 Louisville 1979 Donghai 2016 Zvornik 2018 Rüti 2018 Québec 2025 Key figures 2025 (in CHF million) Sales 115 5yrs CAGR 4.8% EBITDA 24 EBITDA margin 21% Employees 452 Amongst Top 3 worldwide in molecular sieves for healthcare and industrial applications and in deuterated products 1 Global presence close to customers o 6 production sites o 11 distribution offices o More than 60 countries covered Complemented offering with high-value chromatography gels o Acquisition of SiliCycle in July 2025 1 Estimations of management CPH Group Media and Investors' Conference of 18 February 2026 32
Page 33
Molecular sieves o Molecular sieves are used in removing unwanted molecules and in purifying gas such as natural and industrial gases as well as liquids such as ethanol and to enable oxygen production for life-saving oxygen therapy. Chromatography gels o Highly porous gels for molecular separation for use in the purification process of, for example, manufacture of API, omega-3 fatty acids and support cardiovascular health. Deuterated products o Hydrogen atom in different molecules is replaced by deuterium for use in pharmaceuticals (API), electronics (OLED) and nuclear magnetic resonance (NMR). Zeochem Product portfolio improves quality of life and enables energy transition CPH Group Media and Investors' Conference of 18 February 2026 33
Page 34
Market overview Global fragmented market with growth 2-3%1 p.a. Segment molecular sieves CHF 500-700 million1 Industries o Pharmaceuticals o Electronics o Petrochemistry o Manufacturing industries (glass, steel) o Automotive industry o Construction industry o Oxygen generation Leading companies o Honeywell (UOP) o Arkema (CECA) o Zeochem o Grace o Jalon o Hengye Applications o Production of medical and industrial oxygen o Natural gas processing o Ethanol processing o Purification of technical gases o Industrial drying o Air brakes for commercial vehicles Strategic directions o Accelerated development of market in India through Sorbchem o Focus on innovation o Optimizing distribution network o Application development o Cost reduction and efficiency improvement Zeochem Moleculars sieves for industrial applications 1 Estimations of management CPH Group Media and Investors' Conference of 18 February 2026 34
Page 35
Market overview Global fragmented market with growth 5-10%1 p.a. Segment chromatography gels CHF 150-250 million1 Industries o Pharmaceuticals o Biopharmaceuticals o Academia & Universities o Food & Beverage industry o Cosmetics Leading companies o Qingdao Haiwan o Zeochem o Grace o Merck Applications o Separation and analysis of biomolecules, proteins, peptides and other substances o Purification of APIs o Biopharmaceutical manufacturing processes o Analytical separations Strategic directions o Develop potential of high performing products of SiliCycle Inc. o Launch joint projects, use synergies o Focus on innovation o Expanding platform for high-value products o Optimizing distribution network Zeochem Chromatography gels for pharmaceuticals 1 Estimations of management CPH Group Media and Investors' Conference of 18 February 2026 35
Page 36
Market overview Global fragmented market with growth 10%1 p.a. Segment deuterated products CHF 100-150 million1 Industries o Pharmaceuticals o Electronics o Basic research Leading companies o CIL / Otsuka o Zeochem o Sigma Aldrich / Merck Applications o Deuterated reagents for APIs o Deuterated reagents for OLEDs o Deuterium gas o NMR solvents Strategic directions o Focus on innovation o Increased production capacity o ZEOtope brand development o Optimizing distribution network o Continue gaining market share from competition Zeochem Deuterated products for pharmaceuticals and electronics 1 Estimations of management CPH Group Media and Investors' Conference of 18 February 2026 36
Page 37
Perlen Packaging – a true global player Unique position in pharmaceutical packaging Key figures 2025 (in CHF million) Sales 219 5yrs CAGR 6.5% EBITDA 26 EBITDA margin 12% Employees 784 No. 1 worldwide in highest barrier blisters1 and specialized supplier of pharmaceutical bottles with barrier function Global presence close to customers o 7 production sites o 11 distributors and agents in more than 40 countries o More than 85 countries covered Portfolio expansion into complementary primary pharmaceutical packaging o Acquisition of LOG Pharma in February 2025 2 Estimations of management Whippany 2006 Müllheim 2007 Anápolis 2018 Perlen 1954 Suzhou 2016 Tököl 2025 Ashdot Ya’akov Ihud 2025 CPH Group Media and Investors' Conference of 18 February 2026 37
Page 38
Perlen Packaging Pharmaceutical packaging with best protection for medicines Barrier effect *Std. HDPE Bottle Bottles and containers Films for tablet blisters Up to 4x better* water vapour barrier Up to 2x better* Effectiveness of water vapour barrier 50x better* Effectiveness of oxygen barrier 100x better* Effectiveness of oxygen barrier 100x better* Effectiveness of oxygen barrier Up to 4x better* Effectiveness of water vapour barrier CPH Group Media and Investors' Conference of 18 February 2026 38
Page 39
Global pharmaceutical bottle market: CHF 8 billion1 Growth: 3-6%3 p.a. Leading suppliers in the plastic blister segment: o KP Klöckner Pentaplast o Liveo (formerlys Bilcare) o Perlen Packaging o Tekniplex Gallazzi o ACG Largest markets outlook 20262 o 1: USA o 2: China o 3: Germany o 4: Japan o 5: France o 6: Brazil o 7: UK o 8: Italy o 9: India Strategic directions o Leverage LOG Pharma’s full potential o Expand presence in Latin America o Prioritize innovation o Drive cost reduction and efficiency improvements Perlen Packaging No. 1 worldwide in highest barrier blister1 1 Estimations of management 2 IQVIA Market Prognosis 3 Mordor Intelligence Global pharmaceutical blister market: CHF 2 billion1 Leading suppliers in the barrier bottle segment: o Colorcon o Bormioli Pharma o MITSUBISHI GAS CHEMICAL o Shriji Polymers LLC Growth: 3-6%2 p.a. Global pharmaceutical market CPH Group Media and Investors' Conference of 18 February 2026 39